Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Solid Tumors × zansecimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

Gemcitabine 5 Paclitaxel 3 Nivolumab 3 cobimetinib 2 atezolizumab 2 Ramucirumab 2 Carboplatin 2 zansecimab 1 tocilizumab 1 tivozanib 1 tislelizumab 1 temsirolimus 1 ridaforolimus 1 plocabulin 1 pevonedistat 1 pembrolizumab 1 pamiparib 1 obinutuzumab 1 necitumumab 1 liposomal doxorubicin 1 lenvatinib 1 glasdegib 1 futuximab 1 demplatin pegraglumer 1 birinapant 1 adavosertib 1 Temozolomide 1 TAK-981 1 Sunitinib 1 Specimen Handling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Terminated

62 enrolled 25 charts

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡